Brief: Onxeo divests two non-core products to Vectans Pharma

Valerio Therapeutics SA

31/07/2017 16:46

July 31 (Reuters) - Onxeo Sa  C4X.PA : 
    * ONXEO DIVESTS TWO NON-CORE PRODUCTS IN ORAL PATHOLOGIES TO 
VECTANS PHARMA 
    * WILL RECEIVE AN UPFRONT PAYMENT OF EUR 4 MILLION, AS WELL 
AS A POTENTIAL EARN-OUT PAYMENT 
    * SALE OF TWO HISTORICAL PRODUCTS SITAVIG AND LORAMYC TO 
VECTANS PHARMA 
    * TO ASSIGN TO VECTANS PHARMA ALL ASSETS RELATING TO TWO 
PRODUCTS - NOTABLY PATENTS, REGULATORY AUTHORIZATIONS AND 
OUTSTANDING CONTRACTS 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nBw8fL3bya 
Further company coverage:  C4X.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))